Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2014; 20(17): 5098-5103
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5098
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.5098
Table 4 Side effects in 83 evaluable esophageal cancer cases
Side effects | Group | χ2 | P value | |
Drug group | Non-drug group | |||
Dizziness or burnout | 20 | 8 | 19.28 | 0.000 |
Somnolence | 4 | 0 | - | 0.019 |
Grade III-IV esophagitis | 4 | 6 | 0.06 | 0.812 |
Grade III-IV leukocyte decrease | 2 | 5 | 0.03 | 0.864 |
Grade III-IV platelet decrease | 1 | 3 | 0.02 | 0.961 |
Grade III-IV nausea and vomiting | 3 | 14 | 2.913 | 0.089 |
Anaphylaxis | 0 | 0 | - | 1.000 |
- Citation: Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li Y, Hu LJ, Li DQ. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. World J Gastroenterol 2014; 20(17): 5098-5103
- URL: https://www.wjgnet.com/1007-9327/full/v20/i17/5098.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i17.5098